Residual macrovascular risk in 2013: What have we learned?

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Fruchart, Jean Charles ^a,b   Davignon, Jean ^c   Hermans, Michel P ^d   Al Rubeaan, Khalid ^e   Amarenco, Pierre ^f   Assmann, Gerd ^g   Barter, Philip ^h   Betteridge, John ⁱ   Bruckert, Eric ^j   Cuevas, Ada ^k   Farnier, Michel ^l   Ferrannini, Ele ^m   Fioretto, Paola ⁿ   Genest, Jacques ^o   Ginsberg, Henry N ^p   Gotto, Antonio M ^q   Hu, Dayi ^r   Kadowaki, Takashi ^s   Kodama, Tatsuhiko ^s   Krempf, Michel ^t   Matsuzawa, Yuji ^u   Núñez Cortés, Jesús M ^v   Monfil, Carlos C ^w   Ogawa, Hisao ^x   Plutzky, Jorge ^y   Rader, Daniel J ^z   Sadikot, Shaukat ^aa   Santos, Raul D ^ab   Shlyakhto, Evgeny ^ac   Sritara, Piyamitr ^ad   Sy, Rody ^ae   Tall, Alan ^af   Tan, Chee E ^ag   Tokgözoǧlu, Lale ^ah   Toth, Peter P ^ai   Valensi, Paul ^aj   Wanner, Christoph ^ak   Zambon, Alberto ⁿ   Zhu, Junren ^al   Zimmet, Paul ^am   more..

^a 4010   (Switzerland)

^b Fondation coeur et arteres   (France)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f BICHAT HOSPITAL   (France)

^g Assmann Stiftung fur Pravention   (Germany)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k CLÍNICA LAS CONDES   (Chile)

^l Point Medical   (France)

^m UNIVERSITY OF PISA   (Italy)

ⁿ UNIVERSITY OF PADOVA   (Italy)

^o ROYAL VICTORIA HOSPITAL   (Canada)

^p Och Spine at New York Presbyterian Hospitals   (United States)

^q WEILL CORNELL MEDICAL COLLEGE   (United States)

^r PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^s UNIVERSITY OF TOKYO   (Japan)

^t NANTES UNIVERSITY HOSPITAL   (France)

^u SUMITOMO HOSPITAL   (Japan)

^v HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^w UNIVERSITY OF CONCEPCIÓN   (Chile)

^x KUMAMOTO UNIVERSITY   (Japan)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

^z UNIVERSITY OF PENNSYLVANIA   (United States)

^aa JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^ab UNIVERSITY OF SÃO PAULO   (Brazil)

^ac ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^ad MAHIDOL UNIVERSITY   (Thailand)

^ae UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^af College of Physicians and Surgeons ^*  (United States)

^ag GLENEAGLES HOSPITAL   (Singapore)

^ah HACETTEPE UNIVERSITY   (Turkey)

^ai UNIVERSITY OF ILLINOIS   (United States)

^aj UNIVERSITÉ PARIS 13   (France)

^ak UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^al FUDAN UNIVERSITY   (China)

^am BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

more..

Author keywords

Atherogenic dyslipidaemia; Residual cardiovascular risk; Therapeutic options; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RESIDUAL CARDIOVASCULAR RISK; REVIEW; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; LEARNING; RISK FACTORS;

EID: 84892772956     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-26     Document Type: Review

References (111)

1. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M. European Cardiovascular Disease Statistics 2012 2012, Sophia Antipolis: European Heart Network, Brussels, European Society of Cardiology.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012, 380:2095-2128. 10.1016/S0140-6736(12)61728-0, 23245604.
3. International Diabetes Federation E-Atlas 6th edition 2013, http://www.idf.org/diabetesatlas, International Diabetes Federation.
4. Sun C, Burgner DP, Ponsonby A-L, Saffery R, Huang R-C, Vuillermin PJ, Cheung M, Craig JM. Effects of early-life environment and epigenetics on cardiovascular disease risk in children: highlighting the role of twin studies. Ped Res 2013, 73:523-530.
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952. 10.1016/S0140-6736(04)17018-9, 15364185, INTERHEART Study Investigators.
6. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, Yusuf S, INTERHEART Investigators in Latin America Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007, 115:1067-1074. 10.1161/CIRCULATIONAHA.106.633552, 17339564, INTERHEART Investigators in Latin America.
7. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P, Residual Risk Reduction Initiative (R3I) The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008, 5:319-335. 10.3132/dvdr.2008.046, 18958843, Residual Risk Reduction Initiative (R3I).
8. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees.
9. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 31:811-822.
10. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361. 10.1093/eurheartj/ehr112, 3105250, 21531743, European Atherosclerosis Society Consensus Panel.
11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG).
12. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis 2013, 23:799-807. 10.1016/j.numecd.2013.05.002, 23932901.
13. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. 10.1001/jama.2009.1619, 3284229, 19903920, The Emerging Risk Factors Collaboration.
14. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Muenster (PROCAM) study. Circulation 2002, 105:310-315. 10.1161/hc0302.102575, 11804985.
15. Besler C, Heinrich K, Riwanto M, Lüscher TF, Landmesser U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des 2010, 16:1480-1493. 10.2174/138161210791051013, 20196740.
16. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) Study. Eur J Clin Invest 2007, 37:925-932. 10.1111/j.1365-2362.2007.01888.x, 18036028.
17. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580. 10.1016/S0140-6736(12)60312-2, 3419820, 22607825.
18. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009, 50(suppl):S195-S200. 2674714, 19033213.
19. Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-1919. 10.1161/CIRCULATIONAHA.111.066589, 22508840.
20. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563. 10.1161/CIRCULATIONAHA.105.565135, 16534013.
21. Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 2008, 57:77-83. 10.1016/j.metabol.2007.08.009, 2194640, 18078862.
22. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374. 10.1124/pr.58.3.1, 16968945.
23. Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafiane A, Krimbou L, Laboissiere S, Genest J. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 2012, 1821:405-415. 10.1016/j.bbalip.2011.07.013, 21840418.
24. Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012, 4:251-268. 10.1002/emmm.201200224, 3376856, 22431312.
25. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, Lüscher TF, Volpe M, Sinatra R, Cosentino F. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J 2013, 34:3557-3562. 10.1093/eurheartj/eht163, 23704708.
26. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458. 10.1161/CIRCULATIONAHA.106.637793, 17190864.
27. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308. 10.1001/jama.298.3.299, 17635890.
28. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. 2867029, 20452521, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
29. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333. 10.1161/CIR.0b013e3182160726, 21502576, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease.
30. Ginsberg HN. New perspectives on atherogenesis. Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137-2142. 10.1161/01.CIR.0000035280.64322.31, 12379586.
31. Patel S, Puranik R, Nakhla S, Lundman P, Stocker R, Wang XS, Lambert G, Rye KA, Barter PJ, Nicholls SJ, Celermajer DS. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 2009, 204:424-428. 10.1016/j.atherosclerosis.2008.07.047, 19111829.
32. Palmer AM, Murphy N, Graham A. Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis 2004, 173:27-38. 10.1016/j.atherosclerosis.2003.12.001, 15177121.
33. Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004, 109:1918-1925. 10.1161/01.CIR.0000125278.58527.F3, 15117861.
34. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436. 10.1016/j.jacc.2012.08.1026, 23265341.
35. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, Yoshimura M, Ogawa H, Fujioka D, Kugiyama K. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004, 43:2219-2224. 10.1016/j.jacc.2003.09.074, 15193683.
36. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, Kodama Y, Mende A, Ichigi Y, Fujioka D, Saito Y, Kugiyama K. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005, 181:321-327. 10.1016/j.atherosclerosis.2005.01.012, 16039286.
37. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010, 106:757-763. 10.1016/j.amjcard.2010.05.002, 20816113.
38. Assmann G, Cullen P, Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case-control study. Diab Vasc Dis Res 2010, 7:204-212. 10.1177/1479164110372640, 20643700.
39. The International Atherosclerosis Society An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Full report http://www.athero.org/download/IASPPGuidelines_FullReport_20131011.pdf, The International Atherosclerosis Society.
40. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis 2012, 11:132. 10.1186/1476-511X-11-132, 3539971, 23046637.
41. Hermans MP, Ahn SA, Rousseau MF. Log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 2010, 9:88. 10.1186/1475-2840-9-88, 3020173, 21156040.
42. Onat A, Can G, Kaya H, Hergenç G. " Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol 2010, 4:89-98. 10.1016/j.jacl.2010.02.005, 21122635.
43. The Look AHEAD Research Group Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154. The Look AHEAD Research Group.
44. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012, 11:125. 10.1186/1475-2840-11-125, 3489608, 23057687.
45. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498. 10.2337/dc08-1543, 2646035, 18984774, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.
46. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP, ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med 2010, 362:1563-1574. ACCORD Study Group.
47. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-684.
48. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884. 10.1016/S0140-6736(10)60656-3, 20462635.
49. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation?. Curr Opin Clin Nutr Metab Care 2004, 7:369-375. 10.1097/01.mco.0000134358.46159.61, 15192437.
50. Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJP, Stroes ESG, Kuivenhoven JA. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006, 26:1236-1245. 10.1161/01.ATV.0000219283.10832.43, 16574898.
51. Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 2013, 36:422-428. 10.2337/dc11-2556, 3554305, 23033246.
52. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG, FIELD study investigators Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697. 10.1016/S0140-6736(07)61607-9, 17988728, FIELD study investigators.
53. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ, ACCORD Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244. ACCORD Study Group.
54. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. FIELD study investigators.
55. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC, FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009, 373:1780-1788. 10.1016/S0140-6736(09)60698-X, 2687887, 19465233, FIELD study investigators.
56. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(6A):3C-18C.
57. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 2012, 55:1641-1650. 10.1007/s00125-012-2524-2, 3374398, 22450889.
58. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012, 35:1008-1014. 10.2337/dc11-1811, 3329840, 22432114.
59. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290. 10.1007/s00125-010-1951-1, 21052978, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators.
60. Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K, FIELD Study Investigators Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 2012, 35:218-225. 10.2337/dc11-1109, 3263870, 22210576, FIELD Study Investigators.
61. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267. AIM-HIGH Investigators.
62. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events. The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol 2013, 62:1580-1584. 10.1016/j.jacc.2013.07.023, 23916935.
63. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291. 3640201, 23444397, HPS2-THRIVE Collaborative Group.
64. Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant) http://www.mercknewsroom.com/press-release/research-and-development-news/merck-provides-update-next-steps-tredaptive-extended-rel.
65. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098. 10.1016/S0140-6736(07)60527-3, 17398308, Japan EPA lipid intervention study (JELIS) Investigators.
66. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, JELIS Investigators, Japan Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135-140. 10.1016/j.atherosclerosis.2008.06.003, 18667204, JELIS Investigators, Japan.
67. Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-2026. 10.1056/NEJMoa1003603, 20929341, Alpha Omega Trial Group.
68. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S, ORIGIN Trial Investigators N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318. ORIGIN Trial Investigators.
69. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033. 10.1001/2012.jama.11374, 22968891.
70. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT Trial. J Natl Cancer Inst 2013, 105:1132-1141. 10.1093/jnci/djt174, 23843441.
71. Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2011, 173:1429-1439. 10.1093/aje/kwr027, 3145396, 21518693.
72. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event REDUCE-IT) [http://clinicaltrials.gov/show/NCT01492361.
73. Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261. 10.1016/j.atherosclerosis.2012.02.016, 22410123.
74. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192. 10.1016/S0140-6736(11)60739-3, 3145073, 21663949.
75. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356. 10.1056/NEJMoa0804602, 18765433, SEAS Investigators.
76. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443. 10.1056/NEJMoa0800742, 18376000, ENHANCE Investigators.
77. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston A, Smink RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946-955. 10.1056/NEJM199010043231404, 2205799, and the POSCH Group.
78. Pyǒrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620. 10.2337/diacare.20.4.614, 9096989.
79. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Fukami K, Okuda S, Yamagishi S. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010, 61:58-61. 10.1016/j.phrs.2009.07.011, 19666118.
80. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM, IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826-832. 10.1016/j.ahj.2008.07.023, 19061694, IMPROVE-IT Investigators.
81. Ishibashi S, Arai H, Yamashita S, Araki E, Yamada N. Benefical effects of K-877, a potent and highly selective PPARαagonist, on plasma lipoprotein profile in patients with atherogenic dyslipidemia [abstract] http://www.kenes.com/eas2012/abstracts/pdf/525.pdf.
82. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135. 10.1016/S0140-6736(09)60870-9, 19515415.
83. Younk LM, Uhl L, Davis SN. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol 2011, 7:753-763. 10.1517/17425255.2011.579561, 21521130.
84. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011, 34:2008-2014. 10.2337/dc11-0093, 3161281, 21816979.
85. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P, Determining the Efficacy and Tolerability Investigators. The DEFINE Investigators Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415. 10.1056/NEJMoa1009744, 21082868, Determining the Efficacy and Tolerability Investigators. The DEFINE Investigators.
86. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA 2011, 306:2099-2109.
87. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353. 10.1016/j.jacc.2012.03.007, 22463922.
88. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, LAPLACE-TIMI 57 Investigators Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017. 10.1016/S0140-6736(12)61770-X, 23141813, LAPLACE-TIMI 57 Investigators.
89. Fruchart JC. Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol 2013, 12:82. 10.1186/1475-2840-12-82, 3682868, 23721199.
90. Roche halts investigation of aleglitazar following regular safety review of phase III trial http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm.
91. Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013, 36:2923-2930. 10.2337/dc12-2012, 23715754.
92. Ishibashi S, Yamashita S, Arai H, Araki E, Yamada N. Suppression of postprandial triglyceride, Remnant-like Particles-Cholesterol (RLP-C) and ApoB48 surge by K-877, a potent and highly selective PPARα agonist [abstract] http://www.kenes.com/eas2012/abstracts/pdf/618.pdf.
93. Harano Y, Miyawaki T, Nabiki J, Shibachi M, Adachi T, Ikeda M, Ueda F, Nakano T. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J 2006, 53:173-180. 10.1507/endocrj.53.173, 16618974.
94. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122. 10.1056/NEJMoa0706628, 17984165, ILLUMINATE Investigators.
95. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M, West SH, White V, Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008, 154:1465-1473. 10.1038/bjp.2008.229, 2440088, 18536749.
96. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. New Engl J Med 2012, 367:2089-2099. 10.1056/NEJMoa1206797, 23126252, dal-OUTCOMES Investigators.
97. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification http://clinicaltrials.gov/show/NCT01252953.
98. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE) http://clinicaltrials.gov/show/NCT01687998.
99. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012, 53:2515-2524. 10.1194/jlr.R026658, 3494258, 22811413.
100. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) http://clinicaltrials.gov/ct2/show/NCT01663402.
101. FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk http://clinicaltrials.gov/ct2/show/NCT01764633.
102. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300. 10.1001/jama.290.17.2292, 14600188.
103. Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol 2013, 2013:891403. 3678415, 23781332.
104. Diditchenko S, Gille A, Pragst I, Stadler D, Waelchli M, Hamilton R, Leis A, Wright SD. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol 2013, 33:2202-2211. 10.1161/ATVBAHA.113.301981, 23868939.
105. Nicholls SJ, Ballantyne CM, Barter PJ, Brewer B, Kastelein JJP, Gordon A, Johansson J, Wong N, Puri R, Borgman M, Wolski K, Nissen S. ASSURE: Effect of an Oral Agent Inducing Apo A-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study [abstract 708] http://congress365.escardio.org/Search-Results?presentation=C365PRESENTATION90681&doc=report.
106. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC, Levy D, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, doi: 10.1016/j.jacc.2013.11.002.
107. National Lipid Association NLA Statement on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults https://www.lipid.org/nla/2013-accaha-guideline-treatment-blood-cholesterol-reduce-atherosclerotic-cardiovascular-risk, National Lipid Association.
108. American Association of Clinical Endocrinologists Member alert re. guidelines https://www.aace.com/membership/member_alerts, American Association of Clinical Endocrinologists.
109. European Atherosclerosis Society New guidelines in USA: How do they compare with the EAS/ESC guidelines for the management of dyslipidaemia? http://www.eas-society.org/News.aspx?newsId=316, European Atherosclerosis Society.
110. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJP, on behalf of the DYSIS Investigators Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prevent Cardiol 2012, 19:221-230. on behalf of the DYSIS Investigators.
111. Toth PP, Doyle C, Henriksson K. Prevalence of suboptimal non-high-density lipoprotein cholesterol levels in US adults with hypertriglyceridemia: The National Health and Nutrition Examination Survey 2003-2010 2013, Circulation, 128:A1592.